Cargando…
Does long-term use of antidiabetic drugs changes cancer risk?
Antidiabetic medications are commonly used around the world, but their safety is still unclear. The aim of this study was to investigate whether long-term use of insulin and oral antidiabetic medications is associated with cancer risk. We conducted a well-designed case–control study using 12 years o...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783244/ https://www.ncbi.nlm.nih.gov/pubmed/31577776 http://dx.doi.org/10.1097/MD.0000000000017461 |
_version_ | 1783457528824201216 |
---|---|
author | Liu, Yi-Chun Nguyen, Phung-Anh Humayun, Ayesha Chien, Shuo-Chen Yang, Hsuan-Chia Asdary, Rahma Novita Syed-Abdul, Shabbir Hsu, Min-Huei Moldovan, Max Yen, Yun Li, Yu-Chuan (Jack) Jian, Wen-Shan Iqbal, Usman |
author_facet | Liu, Yi-Chun Nguyen, Phung-Anh Humayun, Ayesha Chien, Shuo-Chen Yang, Hsuan-Chia Asdary, Rahma Novita Syed-Abdul, Shabbir Hsu, Min-Huei Moldovan, Max Yen, Yun Li, Yu-Chuan (Jack) Jian, Wen-Shan Iqbal, Usman |
author_sort | Liu, Yi-Chun |
collection | PubMed |
description | Antidiabetic medications are commonly used around the world, but their safety is still unclear. The aim of this study was to investigate whether long-term use of insulin and oral antidiabetic medications is associated with cancer risk. We conducted a well-designed case–control study using 12 years of data from Taiwan's National Health Insurance Research Database and investigated the association between antidiabetic medication use and cancer risk over 20 years. We identified 42,500 patients diagnosed with cancer and calculated each patient's exposure to antidiabetic drugs during the study period. We matched cancer and noncancer subjects matched 1:6 by age, gender, and index date, and used Cox proportional hazard regression and conditional logistic regression, adjusted for potential confounding factors, that is, medications and comorbid diseases that could influence cancer risk during study period. Pioglitazone (adjusted odds ratio [AOR], 1.20; 95% confidence interval [CI], 1.05–1.38); and insulin and its analogs for injection, intermediate or long acting combined with fast acting (AOR, 1.22; 95% CI, 1.05–1.43) were significantly associated with a higher cancer risk. However, metformin (AOR, 1.00; 95% CI, 0.93–1.07), glibenclamide (AOR, 0.98; 95% CI, 0.92–1.05), acarbose (AOR, 1.06; 95% CI, 0.96–1.16), and others do not show evidence of association with cancer risk. Moreover, the risk for specific cancers among antidiabetic users as compared with nonantidiabetic medication users was significantly increased for pancreas cancer (by 45%), liver cancer (by 32%), and lung cancer (by 18%). Antidiabetic drugs do not seem to be associated with an increased cancer risk incidence except for pioglitazone, insulin and its analogs for injection, intermediate or long acting combined with fast acting. |
format | Online Article Text |
id | pubmed-6783244 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-67832442019-11-13 Does long-term use of antidiabetic drugs changes cancer risk? Liu, Yi-Chun Nguyen, Phung-Anh Humayun, Ayesha Chien, Shuo-Chen Yang, Hsuan-Chia Asdary, Rahma Novita Syed-Abdul, Shabbir Hsu, Min-Huei Moldovan, Max Yen, Yun Li, Yu-Chuan (Jack) Jian, Wen-Shan Iqbal, Usman Medicine (Baltimore) 4200 Antidiabetic medications are commonly used around the world, but their safety is still unclear. The aim of this study was to investigate whether long-term use of insulin and oral antidiabetic medications is associated with cancer risk. We conducted a well-designed case–control study using 12 years of data from Taiwan's National Health Insurance Research Database and investigated the association between antidiabetic medication use and cancer risk over 20 years. We identified 42,500 patients diagnosed with cancer and calculated each patient's exposure to antidiabetic drugs during the study period. We matched cancer and noncancer subjects matched 1:6 by age, gender, and index date, and used Cox proportional hazard regression and conditional logistic regression, adjusted for potential confounding factors, that is, medications and comorbid diseases that could influence cancer risk during study period. Pioglitazone (adjusted odds ratio [AOR], 1.20; 95% confidence interval [CI], 1.05–1.38); and insulin and its analogs for injection, intermediate or long acting combined with fast acting (AOR, 1.22; 95% CI, 1.05–1.43) were significantly associated with a higher cancer risk. However, metformin (AOR, 1.00; 95% CI, 0.93–1.07), glibenclamide (AOR, 0.98; 95% CI, 0.92–1.05), acarbose (AOR, 1.06; 95% CI, 0.96–1.16), and others do not show evidence of association with cancer risk. Moreover, the risk for specific cancers among antidiabetic users as compared with nonantidiabetic medication users was significantly increased for pancreas cancer (by 45%), liver cancer (by 32%), and lung cancer (by 18%). Antidiabetic drugs do not seem to be associated with an increased cancer risk incidence except for pioglitazone, insulin and its analogs for injection, intermediate or long acting combined with fast acting. Wolters Kluwer Health 2019-10-04 /pmc/articles/PMC6783244/ /pubmed/31577776 http://dx.doi.org/10.1097/MD.0000000000017461 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 |
spellingShingle | 4200 Liu, Yi-Chun Nguyen, Phung-Anh Humayun, Ayesha Chien, Shuo-Chen Yang, Hsuan-Chia Asdary, Rahma Novita Syed-Abdul, Shabbir Hsu, Min-Huei Moldovan, Max Yen, Yun Li, Yu-Chuan (Jack) Jian, Wen-Shan Iqbal, Usman Does long-term use of antidiabetic drugs changes cancer risk? |
title | Does long-term use of antidiabetic drugs changes cancer risk? |
title_full | Does long-term use of antidiabetic drugs changes cancer risk? |
title_fullStr | Does long-term use of antidiabetic drugs changes cancer risk? |
title_full_unstemmed | Does long-term use of antidiabetic drugs changes cancer risk? |
title_short | Does long-term use of antidiabetic drugs changes cancer risk? |
title_sort | does long-term use of antidiabetic drugs changes cancer risk? |
topic | 4200 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783244/ https://www.ncbi.nlm.nih.gov/pubmed/31577776 http://dx.doi.org/10.1097/MD.0000000000017461 |
work_keys_str_mv | AT liuyichun doeslongtermuseofantidiabeticdrugschangescancerrisk AT nguyenphunganh doeslongtermuseofantidiabeticdrugschangescancerrisk AT humayunayesha doeslongtermuseofantidiabeticdrugschangescancerrisk AT chienshuochen doeslongtermuseofantidiabeticdrugschangescancerrisk AT yanghsuanchia doeslongtermuseofantidiabeticdrugschangescancerrisk AT asdaryrahmanovita doeslongtermuseofantidiabeticdrugschangescancerrisk AT syedabdulshabbir doeslongtermuseofantidiabeticdrugschangescancerrisk AT hsuminhuei doeslongtermuseofantidiabeticdrugschangescancerrisk AT moldovanmax doeslongtermuseofantidiabeticdrugschangescancerrisk AT yenyun doeslongtermuseofantidiabeticdrugschangescancerrisk AT liyuchuanjack doeslongtermuseofantidiabeticdrugschangescancerrisk AT jianwenshan doeslongtermuseofantidiabeticdrugschangescancerrisk AT iqbalusman doeslongtermuseofantidiabeticdrugschangescancerrisk |